Second-line chemotherapy in head and neck cancer: what should we expect?

References

• Lester EP, Kinnealey A, Matz GJ. Sequential combination chemotherapy for advanced squamous cell carcinoma of the head and neck. Laryngoscope89(12), 1921–1929 (1979).
   PubMedGoogle Scholar
• Jahnke V. Experiences using combination chemotherapy with cis-platinum, bleomycin and methotrexate in the management of advanced squamous cell carcinomas of the head and neck. HNO28, 405–408 (1980).
   PubMedGoogle Scholar
• Wendt TG, Grabenbauer GG, Rodel CM et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J. Clin. Oncol.16, 1318–1324 (1998).
   PubMed Web of Science ®Google Scholar
• Schäfer U, Schüller P, Micke O, Willich N. Simultaneous radiochemtherapy versus concomitant boost radiation for advanced inoperable head and neck cancer. Acta Oncologica39, 523–528 (2000).
   PubMedGoogle Scholar
• Mücke R, Blynow M, Ziegler PG et al. Concurrent radiotherapy and chemotherapy with carboplatin in patients with unresectable advanced head and neck tumors stages III and IV. Strahlenther. Onkol.175, 213–217 (1999).
   PubMedGoogle Scholar
• Kaplan MJ, Hahn SS, Johns ME, Stewart FE, Constable WC, Cantrell RW. Mitomycin and fluorouracil with concomitant radiotherapy in head and neck cancer. Arch. Otolaryngol.111, 220–222 (1985).
   PubMedGoogle Scholar
• Micke O, Matzkies F, Mücke R et al. Magnesium and zinc balance in cisplatinum-based radiochemotherapy in advanced head and neck cancer patients. Trace Elements Electrolytes25, 234 (2008).
   Google Scholar
• Büntzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, DeVries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled Phase III study. Int. J. Radiat. Oncol. Biol. Phys.64, 684–691 (2006).
   PubMed Web of Science ®Google Scholar
• Büntzel J, Glatzel M, Bruns F, Kisters K, Micke O, Muecke R. Selenium supplementation in head and neck surgery. Trace Elements and Electrolytes25, 221 (2008).
   Google Scholar
• Forastiere AA. Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin. Oncol.21(Suppl. 8), 49–52 (1994).
   PubMed Web of Science ®Google Scholar
• Benasso M, Numico G, Rosso R, Merlano M, Ricci I, Gentile A. Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study. Semin. Oncol.24 (Suppl. 19), 46–50 (1997).
   Google Scholar
• Büntzel J, Schuth J, Glatzel M. Doxorubicin in the palliative therapy of recurrent pretreated head and neck cancer. Proc. ASCO21, 2556(a) (2002).
   Google Scholar
• Stewart J, Lewanski C, Harrington K, Northcote D, Welbank H, Whittaker J. Comparison of pegylated liposomal doxorubcin (PLD) and pegylated liposomal cisplatinum (PLC) in patients with advanced head and neck squamous cell carcinoma (HNSCC). Proc. ASCO19, 1672(a) (2000).
   Google Scholar
• Zhang Q, Huang XE, Gao LL. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed. Pharmacother. DOI: 10.1016/j.biopha.2008.10.001 (2008) (Epub ahead of print).
   Google Scholar
• Posner MR, Hershock DM, Blajman CR et al.; the TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med.357, 1705–1715 (2007).
   PubMed Web of Science ®Google Scholar
• Pignon J, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet355, 949–955 (2000).
   PubMed Web of Science ®Google Scholar
• Harari PM. Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? J. Clin. Oncol.15, 2050–2055 (1997).
   PubMedGoogle Scholar
• Silverman S Jr, Gorsdy M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer53, 563–568 (1984).
   PubMed Web of Science ®Google Scholar
• Hong WK, Lippman SM, Itri LM et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N. Engl. J. Med.323, 79.801 (1990).
   Google Scholar
• Wan H, Oridate N, Lotan D, Hong WK, Lotan R. Overexpression of retinoic acid receptor β in head and neck squamous cell carcinoma cells increases their sensitivity to retinoid-induced suppression of squamous differentiation by retinoids. Cancer Res.59, 3518–3526 (1999).
   PubMedGoogle Scholar
• Mertens R, Granzen B, Lassay L et al. Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC-91-GPOH). Cancer104, 1083–1089 (2005).
   PubMed Web of Science ®Google Scholar
• Padovan I, Brodarec I, Ikic D, Knezevic M, Soos E. Effect of interferon in therapy of skin and head and neck tumors. J. Cancer Res. Clin. Oncol.100, 295–310 (1981).
   PubMedGoogle Scholar
• Brigette BY, Poon TCW, To KF et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma – a prospective study. Head Neck25, 864–872 (2003).
   PubMedGoogle Scholar
• Brockstein B, Lacouture M, Agulnik M. The role of inhibitors of the epidermal growth factor in management of head and neck cancer. J. Natl Compr. Canc. Netw.6(7), 696–706 (2008).
   PubMedGoogle Scholar
• Kirby AM, A’Herm RP, D’Ambrosio C et al. Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer. Br. J. Cancer94, 631–636 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J. Clin. Oncol.22, 1743–1752 (2004).
   PubMed Web of Science ®Google Scholar
• Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin. Biol. Ther.2, 257–268 (2007).
   Google Scholar
• Leon X, Hitt R, Constenla M et al. A retrospective analysis of the outcome of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) who are progressing while on a platinum-based palliative chemotherapy. Proc. ASCO22, 2022 (2003).
   Google Scholar
• Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group Study. Cancer Treat. Rep.69, 577–581 (1985).
   PubMedGoogle Scholar
• Ranieri G, Grammatica L, Patruno R et al. A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. J. Cell Mol. Med.11, 362–368 (2007).
   PubMed Web of Science ®Google Scholar
• Airoldi M, Cortesina G, Giordano C, Pedani F, Bumma C. Ifosfamide in the treatment of head and neck cancer. Oncology65(Suppl. 2), 37–43 (2003).
   PubMedGoogle Scholar
• Al-Sarraf M. Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control9, 387–399 (2002).
   PubMedGoogle Scholar
• Volling P, Schröder M, Rauschning W, Achterrath W, Stennert E. Carboplatin – the better platinum in head and neck cancer? Arch. Otolaryngol. Head Neck Surg.115(6), 695–698 (1989).
   PubMed Web of Science ®Google Scholar
• Jacobs C, Lyman G, Velez-Garcia E et al. A Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol.10, 257–263 (1992).
   PubMed Web of Science ®Google Scholar
• Gibson MK, Li Y, Murphy B et al. Randomized Phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (e1395): an intergroup trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol.23, 3562–3567 (2005).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med.359, 1116–1127 (2008).
   PubMed Web of Science ®Google Scholar
• Guntinas-Lichius O, Tanvetyanon T, Vermorken JB. Cetuximab in head and neck cancer. N. Engl. J. Med.359, 2725–2726 (2008).
   PubMedGoogle Scholar
• Büntzel J, deVries A, Micke O. Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer, J. Clin. Oncol.25, 6077(a) (2007).
   Google Scholar
• Specenier P, Vermorken JB. The role of cetuximab in the treatment of head and neck cancer. BJMO2, 161–167 (2008).
   Google Scholar
• O’Neil BH, Allen R, Spigel DR et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J. Clin. Oncol.25, 3644–3648 (2007).
   PubMed Web of Science ®Google Scholar
• Specenier P, Vermorken JB. Targeted therapies in head and neck cancer. Target. Oncol.2(2), 73–88 (2007).
   Web of Science ®Google Scholar